Results 21 to 30 of about 4,684,794 (400)

Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2022
Importance Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. Objective To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous ...
N. Goldenberg, J. Kittelson, T. Abshire, M. Bonaca, J. Casella, R. Dale, J. Halperin, F. Hamblin, C. Kessler, M. Manco‐Johnson, R. Sidonio, A. Spyropoulos, P. Steg, A. Turpie, S. Schulman   +14 more
semanticscholar   +1 more source

Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis

Scientific Reports, 2022
Disseminated intravascular coagulation (DIC) is one of the major organ dysfunctions associated with sepsis. This retrospective secondary analysis comprised data from a prospective multicenter study to investigate the age-related differences in the ...
Takeshi Wada, Kazuma Yamakawa, Daijiro Kabata, Toshikazu Abe, Hiroshi Ogura, Atsushi Shiraishi, Daizoh Saitoh, Shigeki Kushimoto, Seitaro Fujishima, Toshihiko Mayumi, Toru Hifumi, Yasukazu Shiino, Taka-aki Nakada, Takehiko Tarui, Yasuhiro Otomo, Kohji Okamoto, Yutaka Umemura, Joji Kotani, Yuichiro Sakamoto, Junichi Sasaki, Shin-ichiro Shiraishi, Kiyotsugu Takuma, Ryosuke Tsuruta, Akiyoshi Hagiwara, Tomohiko Masuno, Naoshi Takeyama, Norio Yamashita, Hiroto Ikeda, Masashi Ueyama, Satoshi Fujimi, Satoshi Gando   +30 more
doaj   +1 more source

Anticoagulant Therapy Is Associated With Decreased Long-Term Mortality in Splenic Infarction Patients: A Multicenter Study

Frontiers in Medicine, 2021
Background: Patients with splenic infarction (SI) are associated with a prothrombotic state and are vulnerable to subsequent thromboembolic complications. However, due to its rarity, there is no established treatment modality in this population. We aimed
Chieh-Ching Yen, Chieh-Ching Yen, Chih-Kai Wang, Chih-Kai Wang, Chung-Hsien Chaou, Chung-Hsien Chaou, Chung-Hsien Chaou, Shou-Yen Chen, Shou-Yen Chen, Shou-Yen Chen, Jhe-Ping Lin, Jhe-Ping Lin, Chip-Jin Ng, Chip-Jin Ng   +13 more
doaj   +1 more source

Magnitude of hemorrhagic complications and its associated factors among patients on anticoagulant therapy at University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia

Thrombosis Update, 2023
Background: Despite the well-established effectiveness of anticoagulants, the risk of their hemorrhagic complications withheld many patients from being maintained on anticoagulant therapy. However, there is no sufficient data on the magnitude and factors
Eden Abetu Mehari, Abebe Basazn Mekuria, Mestayet Geta, Eshetie Melese Birru   +3 more
doaj   +1 more source

Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action

British Journal of Haematology, 2020
Emerging evidence shows that severe coronavirus disease 2019 (COVID‐19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism.
A. Kollias, K. Kyriakoulis, E. Dimakakos, G. Poulakou, G. Stergiou, K. Syrigos   +5 more
semanticscholar   +1 more source

Clinical study of anticoagulant therapy in patients with severe coronavirus disease: A single-center retrospective analysis

Vascular Investigation and Therapy, 2021
OBJECTIVE: The prognosis of COVID-19 is related to thrombotic events. This study investigated prognostic risk factors, anticoagulant therapy effects, and potential instruction of treatment or prognostic with D-dimer in patients with severe COVID-19 ...
Peng Zhou, Chuan-Qi Cai, Jin-Song Li, Huan-Zong Jiang, Zun-Xiang Ke, Shan Zhang, Zhong-Jian Wang, Chao Yang, Qin Li, Yi-Qing Li   +9 more
doaj   +1 more source

The year in cardiology: arrhythmias and pacing. [PDF]

, 2020
During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H, Camm, AJ, Lip, GYH, Schilling, R, Steffel, J   +4 more
core   +4 more sources

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Journal of Thrombosis and Thrombolysis, 2020
Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar
G. Barnes, Allison E. Burnett, Arthur L. Allen, Marilyn Blumenstein, N. Clark, A. Cuker, William E Dager, S. Deitelzweig, S. Ellsworth, D. Garcia, S. Kaatz, Tracy Minichiello   +11 more
semanticscholar   +1 more source

Assessment of adherence level of patients on anticoagulant therapy in a tertiary healthcare facility in Uyo, Nigeria

Ibom Medical Journal, 2021
Background: Anticoagulants are highly effective in preventing venous thromboembolism and remains the main stay of treatment. However, strict adherence to medication is essential for maximizing treatment. Objectives: the objectives of this study, were to
Ekwere TA, Ekanem AM, Benson SM
doaj   +1 more source

Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria: a post-hoc analysis of a prospective multicenter observational study

Journal of Intensive Care, 2023
Background The development of disseminated intravascular coagulation (DIC) in patients with sepsis has been repeatedly confirmed as a factor associated with poor prognosis.
Takeshi Wada, Kazuma Yamakawa, Daijiro Kabata, Toshikazu Abe, Seitaro Fujishima, Shigeki Kushimoto, Toshihiko Mayumi, Hiroshi Ogura, Daizoh Saitoh, Atsushi Shiraishi, Yasuhiro Otomo, Satoshi Gando, the JAAM FORECAST Group   +12 more
doaj   +1 more source